David Collingridge

 Dr David Collingridge

Editor-in-Chief, The Lancet Oncology

Dr David Collingridge is the Editor-in-Chief of The Lancet Oncology and Vice President of editorial strategy and innovation for The Lancet’s large portfolio of clinical journals. He holds a PhD in tumour biology from University College London, UK, and has previously done research in translational radiobiology at Yale University, New Haven, CT, USA, and at Imperial College School of Medicine, London, UK. Dr Collingridge has won awards for projects focused on cancer control in low-to-middle income countries including the GHC 2025 Distinguished Global Oncology Leader award; has published numerous peer-review articles, editorials, opinion pieces, and news reports; and has co-authored a textbook on radiobiology. He is currently a Visiting Professor of Global Oncology at King’s College London, UK, and was previously a Clinical Associate Professor in Radiation Medicine at Hofstra University, NY, USA.

Updated: August 2025